share_log

Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $149

Benzinga ·  Dec 19, 2023 08:23

Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $137 to $149.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment